Part of the Oncology Commons
2020
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers, David Peng, B. Rodriguez, Lixia Diao, Pierre Gaudreau, Aparna Padhye, Joshua Ochieng, Caleb Class, Jared Fradette, Laura Gibson, Limo Chen, Jing Wang, Lauren Byers, Don Gibbons
Scholarship and Professional Work – COPHS